David Ambinder, MD

David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.

Articles by David Ambinder, MD

David Ambinder, MDUrothelial Carcinoma | January 16, 2024
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Read More
David Ambinder, MDLocalized | December 4, 2023
Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.
David Ambinder, MDSUO 2023 | November 27, 2023
The SUO meeting pays special attention to patients who responded well to NAC, the BCG shortage, trimodal therapy, and more.
David Ambinder, MDNon-Muscle Invasive Urothelial Carcinoma | October 30, 2023
Is there a better way to manage low-grade NMIBC? Adding UGN-102 to the current standard of care may be the answer.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | October 30, 2023
From presentation with a testicular mass to treatment options, this provides valuable insights for community oncologists.
Aditya Bagrodia, MD, FACSTesticular, Penile, and Rare Malignancies | October 6, 2023
Drs. Bagrodia and Ambinder provide an overview of the care continuum for newly diagnosed testicular cancer patients.
Aditya Bagrodia, MD, FACSTesticular, Penile, and Rare Malignancies | October 6, 2023
Drs. Bagrodia and Ambinder walk through a community urologist's approach to a patient who presents with a testicular mass.
David Ambinder, MDUrothelial Carcinoma | October 2, 2023
A recent study adds to the scant literature on preclinical bladder autotransplantation before a first-in-human trial.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
Unique characteristics include higher stage at presentation and a more aggressive subsequent clinical course.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
It may be time to include RPLND for patients with retroperitoneal disease following treatment for seminoma.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | August 15, 2023
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 28, 2023
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 24, 2023
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Katie S. Murray, DOUpper Tract Urothelial Carcinoma | July 24, 2023
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Katie S. Murray, DOUpper Tract Urothelial Carcinoma | July 24, 2023
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
David Ambinder, MDUpper Tract Urothelial Carcinoma | June 28, 2023
The recently released AUA/SUO guideline on UTUC includes 6 guidelines on neoadjuvant/adjuvant chemotherapy and immunotherapy.
David Ambinder, MDUpper Tract Urothelial Carcinoma | May 31, 2023
There are 7 recommendations specific to the appropriateness of and proper technique for kidney-sparing management.
David Ambinder, MDUpper Tract Urothelial Carcinoma | May 30, 2023
The recent AUA/SUO guideline on the management of non-metastatic UTUC includes 2 recommendations for lymph node dissection.